Skip to Main Content

After months of planning, the Louisiana Department of Health has chosen a new Gilead Sciences (GILD) subsidiary to supply a hepatitis C medicine under a so-called Netflix payment model.

The deal revolves around subscription-based payments. Asegua Therapeutics, the Gilead unit, has agreed to provide the state Medicaid program and Department of Corrections with unlimited access to an authorized generic version of the Epclusa treatment for a fixed amount of money for five years, according to the state Department of Health. A contract is expected to be finalized by June 1.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!